-       Report 
   - August 2023
    -  70 Pages 
    South Korea
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - August 2023
    -  150 Pages 
    North America
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    New Zealand
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  100 Pages 
    Asia Pacific
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  80 Pages 
    Europe
   
   From       €4269EUR$4,750USD£3,744GBP 
                 -       Report 
   - February 2024
    -  80 Pages 
    North America
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  90 Pages 
    Asia Pacific
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  80 Pages 
    Latin America
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  80 Pages 
    Europe
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    Iran
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    Indonesia
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    Philippines
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    India
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - August 2023
    -  110 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - August 2023
    -  80 Pages 
    Africa, Middle East
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - October 2022
    -  70 Pages 
    Africa
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - May 2024
    -  140 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Report 
   - May 2023
    -  147 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - June 2025
    -  250 Pages 
    Canada
   
   From       €2507EUR$2,789USD£2,198GBP 
                -       Report 
   - August 2024
    -  150 Pages 
    Global
   
   From       €2507EUR$2,789USD£2,198GBP 
             
         Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive    market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less   Read more